Streetbeat News

Revenues

CROX

Crocs shares declined following the release of Q3 financial results and a reduction in revenue guidance for the HEYDUDE Brand.

Portfolio Pulse from Benzinga Newsdesk

October 29, 2024 | 11:47 am

NARI

Inari Medical shares rose after the company reported strong Q3 sales and increased its FY24 revenue guidance. Piper Sandler maintained a Neutral rating but raised the price target from $50 to $52.

Portfolio Pulse from Benzinga Newsdesk

October 29, 2024 | 11:47 am

CVLT

CommVault Systems reported better-than-expected Q2 2025 results with adjusted EPS of $0.83, surpassing the estimate of $0.76, and sales of $233.278 million, exceeding the expected $220.779 million.

Portfolio Pulse from Benzinga Newsdesk

October 29, 2024 | 11:46 am

PERF

Perfect anticipates a year-over-year total revenue growth rate of 12% to 14% for 2024, compared to 2023.

Portfolio Pulse from Benzinga Newsdesk

October 29, 2024 | 11:43 am

CBZ

CBIZ has reaffirmed its FY2024 adjusted EPS guidance at $2.64-2.69, aligning with analyst estimates. The company also expects total revenue growth of 7% to 9% over the prior year, maintaining its sales outlook at $1.70 billion-1.73 billion, which is below the $2.13 billion estimate.

Portfolio Pulse from Benzinga Newsdesk

October 29, 2024 | 11:38 am

HUBB

Hubbell has revised its FY24 sales growth expectations, now anticipating total sales growth of approximately 6%, down from the previous estimate of 7-8%. Organic net sales growth is also expected to be around 1%, reduced from the prior view of 3%.

Portfolio Pulse from Benzinga Newsdesk

October 29, 2024 | 11:38 am

HNI

HNI reported Q3 2024 earnings per share of $1.03, surpassing the analyst estimate of $0.98. However, sales were $672.2 million, falling short of the $712.629 million estimate and down 5.54% from the previous year.

Portfolio Pulse from Benzinga Newsdesk

October 29, 2024 | 11:34 am

KNSA

Kiniksa Pharmaceuticals has updated its 2024 net product revenue guidance for Arcalyst to $410M-$420M, up from the previous $405M-$415M. The company also expects to remain cash flow positive annually.

Portfolio Pulse from Benzinga Newsdesk

October 29, 2024 | 11:33 am

NWBI

Northwest Bancshares reported Q3 2024 earnings per share of $0.26, meeting analyst expectations, and sales of $111.302 million, surpassing estimates by 1.43%. Sales increased by 2.71% compared to the same period last year.

Portfolio Pulse from Benzinga Newsdesk

October 29, 2024 | 11:33 am

HRMY

Harmony Biosciences has reiterated its full-year 2024 net product revenue guidance, expecting revenue between $700 million and $720 million.

Portfolio Pulse from Benzinga Newsdesk

October 29, 2024 | 11:33 am